Inhibition of Phosphoglycerate Kinase 1 (PGK1) Decreases Neointimal Hyperplasia after Patch Angioplasty
ACS Applied Bio Materials · 2025
DOI: 10.1021/acsabm.5c00589 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2025. Verfasst von Peng Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery Center, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vascular Diseases, Capital Medical U…. Hauptthemen laut MEDLINE: Phosphoglycerate Kinase, Hyperplasia, Neointima, Angioplasty. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Capital Medical University, National Outstanding Youth Science Fund Project of National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Neointimal hyperplasia is a known complication following aorta interventions. In this study, our hypothesis was that inhibiting phosphoglycerate kinase 1 (PGK1) could effectively reduce aortic neointimal hyperplasia in a rat model of abdominal aortic patch angioplasty. The role of the glycolytic pathway in patch angioplasty was analyzed by next-generation sequencing data, and the core role of PGK1 was found by differential gene analysis. The rats were allocated into two distinct groups: a control group that did not receive any supplementary treatment and a group treated with NG52, an inhibitor of PGK1, which was administered via a PLGA coating. Abdominal aortic patches were surgically implanted in the rats and subsequently harvested on the 14th day postimplantation for further analysis. Immunohistochemical analysis identified the presence of PGK1-positive cells within the neointima of the rat model subjected to abdominal aortic patch angioplasty. Importantly, the use of NG52 PLGA coating significantly decreased neointimal thickness (p < 0.0001). The mechanism of action of NG52 may involve the inhibition of TGFβ1 expression and the activation of the signaling pathway. Consequently, targeting the PGK1 pathway holds promise as a therapeutic strategy to mitigate aortic neointimal hyperplasia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery Center, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vascular Diseases, Capital Medical University, Beijing 100013, China.
- School of Material Science and Engineering & Henan Key Laboratory of Advanced Magnesium Alloy & Key Laboratory of Materials Processing and Mold Technology (Ministry of Education), Zhengzhou University, Zhengzhou 450001,…
ORCID-Profile: Peng Sun, Jing'an Li
Förderung
- Capital Medical University
- National Outstanding Youth Science Fund Project of National Natural Science Foundation of China
- National Natural Science Foundation of China
- High-Level Research Special Project for Disciplinary Construction, Beijing Anzhen Hospital Affiliated to Capital Medical University
Zitieren
APA
Sun, P., Cui, H., Ren, C., Xu, C., Yue, C., Li, J., & Lai, Y. (2025). Inhibition of Phosphoglycerate Kinase 1 (PGK1) Decreases Neointimal Hyperplasia after Patch Angioplasty. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c00589
Vancouver
Sun P, Cui H, Ren C, Xu C, Yue C, Li J, et al. Inhibition of Phosphoglycerate Kinase 1 (PGK1) Decreases Neointimal Hyperplasia after Patch Angioplasty. ACS Applied Bio Materials. 2025. doi:10.1021/acsabm.5c00589
BibTeX
@article{Sun2025,
author = {Sun, Peng and Cui, Hao and Ren, Changwei and Xu, Chenzhen and Yue, Chuanjie and Li, Jing'an and Lai, Yongqiang},
title = {Inhibition of Phosphoglycerate Kinase 1 (PGK1) Decreases Neointimal Hyperplasia after Patch Angioplasty},
journal = {ACS Applied Bio Materials},
year = {2025},
doi = {10.1021/acsabm.5c00589}
}
EUVIMED